Applying epigenetics to alzheimer's disease via the latent early-life associated regulation (LEARn) model

Current Alzheimer Research

Volumn 9, Issue 5, 2012, Pages 589-599

  Maloney, Bryan ^a   Sambamurti, Kumar ^b   Zawia, Nasser ^c   Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Alzheimer; Envirome; Environment; Epigenetics; Epigenome; Heavy metal toxicity; Lead toxicity; Methylation; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CLUSTERIN; COMPLEMENT COMPONENT C1R; DNA BASE; GUANINE; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PRESENILIN 1; PRESENILIN 2;

AGING; ALZHEIMER DISEASE; CLINICAL ASSESSMENT TOOL; DEGENERATIVE DISEASE; DEMENTIA; DEVELOPMENTAL STAGE; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; FAMILIAL ALZHEIMER DISEASE; FAMILIAL DISEASE; FEMINIZATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; HEREDITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; LATENT EARLY LIFE ASSOCIATED REGULATION MODEL; LATENT PERIOD; MENTAL RETARDATION MALFORMATION SYNDROME; MILD COGNITIVE IMPAIRMENT; NEUROCHEMISTRY; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 84861123503     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800617955     Document Type: Review

References (154)

1. Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement 7: 208-244 (2011).
2. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr71 (2011).
3. Secher M, Soto M, Gillette S, Andrieu S, Villars H, Vellas B, et al. Balneotherapy, prevention of cognitive decline and care the Alzheimer patient and his family: outcome of a multidisciplinary workgroup. J Nutr Health Aging 13: 797-806 (2009).
4. Gruffydd E, Randle J. Alzheimer's disease and the psychosocial burden for caregivers. Community Pract 79:15-18 (2006).
5. Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 23:177-193 (2011).
6. Lahiri DK, Farlow MR, Greig NH, Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Devel Res 56:267-281 (2002).
7. Karim S, Minhas HM, Bhattacharya S, Sein K, Nayar B, Morris J, et al. The symptomatology of Alzheimer's disease: a cross-cultural study. Int J Geriatr Psychiatry 26: 415-422 (2011).
8. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7: 656-664 (2010).
9. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110: 1129-1134 (2009).
10. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279: 37061-37068 (2004).
11. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525 (2002).
12. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106: 14745-14750 (2009).
13. Brunnstrom H, Englund E. Comparison of four neuropathological scales for Alzheimer's disease. Clin Neuropathol 30: 56-69 (2011).
14. Tayler H, Fraser T, Miners JS, Kehoe PG, Love S. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-beta. J Alzheimers Dis 22: 1363-1373 (2010).
15. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 19: 221-228 (2010).
16. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, Lahti T, et al. Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 7: 280-286 (2010).
17. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67: 505-512 (2010).
18. Garcia-Lara JM, Aguilar-Navarro S, Gutierrez-Robledo LM, Avila-Funes JA. The metabolic syndrome, diabetes, and Alzheimer's disease. Rev Invest Clin 62: 343-349 (2010).
19. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9: 399-417 (2010).
20. Bhat NR. Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J Neurochem 115: 551-562 (2010).
21. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674 (1992).
22. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870 (1996).
23. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 66: S79-85 (2006).
24. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923 (1993).
25. Olarte L, Schupf N, Lee JH, Tang MX, Santana V, Williamson J, et al. Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics. Arch Neurol 63:1586-1590 (2006).
26. Lendon CL, Martinez A, Behrens IM, Kosik KS, Madrigal L, Norton J, et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Human mutation 10: 186-195 (1997).
27. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472 (1993).
28. Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. The AlzGene Database, http://www.alzgene.org/. Alzheimer Research Forum (2011), Accessed: 1 December 2011.
29. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 13 Spec No 1: R135-141 (2004).
30. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 19: 3295-3301 (2010).
31. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ, et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging 32: 756 e711-755 (2011).
32. Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 68: 320-328 (2011).
33. Ge Y-W, Maloney B, Alley GM, Lahiri DK. Important Differences between Human and Mouse APOE Gene Promoters: Implications in Alzheimer's Disease. J Neurochem 103: 1237-1257 (2007).
34. Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, et al. APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol 61: 1434-1439 (2004).
35. Lv H, Jia L, Jia J. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Neurobiol Aging 29: 194-202 (2008).
36. Lahiri DK, Wavrant De-Vrieze F, Ge Y-W, Maloney B, Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. Neurobiol Aging 26: 1329-1341 (2005).
37. Wang S, Jia J. Promoter polymorphisms which modulate BACE1 expression are associated with sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 153B: 159-166 (2010).
38. Sun W, Jia J. The +347 C promoter allele up-regulates MAPT expression and is associated with Alzheimer's disease among the Chinese Han. Neuroscience letters 450: 340-343 (2009).
39. Zuo X, Jia J. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease. Brain Res 1249: 1-8 (2009).
40. Ogunniyi A, Baiyewu O, Gureje O, Hall KS, Unverzagt F, Siu SH, et al. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. Eur J Neurol 7: 485-490 (2000).
41. Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 25: 625-633 (2003).
42. Miller DB, O'Callaghan JP. Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Metabolism: clinical and experimental 57 Suppl 2: S44-49 (2008).
43. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, et al. Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J 20: 788-790 (2006).
44. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 279: 20378-20386 (2004).
45. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5: 535-551 (2004).
46. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig NH, Lahiri DK, et al. Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 5: 517-528 (2004).
47. Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. J Alzheimers Dis 4: 523-529 (2002).
48. Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci USA 98: 3440-3445 (2001).
49. Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol 59: 182-185 (2006).
50. Lahiri DK, Maloney B. The LEARn (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 45: 291-296 (2010).
51. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and betaamyloid in the aging brain. J Neurosci 25: 823-829 (2005).
52. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14: 992-1003 (2009).
53. Wachsman JT. DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 375: 1-8 (1997).
54. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29: 68-72 (2011).
55. Ghosh R, Mitchell DL. Effect of oxidative DNA damage in promoter elements on transcription factor binding. Nucleic Acids Res 27: 3213-3218 (1999).
56. Kuo MH, vom Baur E, Struhl K, Allis CD. Gcn4 activator targets Gcn5 histone acetyltransferase to specific promoters independently of transcription. Mol Cell 6: 1309-1320 (2000).
57. Sims RJ, 3rd, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet 19: 629-639 (2003).
58. Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med 48: 895-904 (2010).
59. Wu J, Basha MR, Zawia NH. The environment, epigenetics and amyloidogenesis. J Mol Neurosci 34: 1-7 (2008).
60. Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15: 827-832 (2001).
61. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68: 1-11 (2008).
62. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. Sadenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28: 195-204 (2005).
63. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging 31: 2025-2037 (2010).
64. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 4: e6617 (2009).
65. Wu G, Bazer FW, Cudd TA, Meininger CJ, Spencer TE. Maternal nutrition and fetal development. J Nutr 134: 2169-2172 (2004).
66. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr 135: 1382-1386 (2005).
67. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 299: 2877-2883 (2008).
68. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698 (2008).
69. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854 (2004).
70. Hughes LA, van den Brandt PA, de Bruine AP, Wouters KA, Hulsmans S, Spiertz A, et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One 4: e7951 (2009).
71. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 286: 355-365 (2003).
72. Kim KY, Kim DS, Lee SK, Lee IK, Kang JH, Chang YS, et al. Association of low-dose exposure to persistent organic pollutants with global DNA hypomethylation in healthy Koreans. Environmental health perspectives 118: 370-374 (2010).
73. Desaulniers D, Xiao GH, Lian H, Feng YL, Zhu J, Nakai J, et al. Effects of mixtures of polychlorinated biphenyls, methylmercury, and organochlorine pesticides on hepatic DNA methylation in prepubertal female Sprague-Dawley rats. Int J Toxicol 28: 294-307 (2009).
74. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14: 992-1003 (2009).
75. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8: 253-262 (2007).
76. Heindel JJ, McAllister KA, Worth L, Jr., Tyson FL. Environmental epigenomics, imprinting and disease susceptibility. Epigenetics 1: 1-6 (2006).
77. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain. Cell 145: 423-434 (2011).
78. Muenzel M, Globisch D, Bruekl T, Wagner M, Welzmiller V, Michalakis S, et al. Quantification of the Sixth DNA Base Hydroxymethylcytosine in the Brain. Angew Chem Intl Ed 49: 5375-5377 (2010).
79. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324: 929-930 (2009).
80. Lee YA, Durandin A, Dedon PC, Geacintov NE, Shafirovich V. Oxidation of guanine in G, GG, and GGG sequence contexts by aromatic pyrenyl radical cations and carbonate radical anions: relationship between kinetics and distribution of alkali-labile lesions. J Phys Chem B 112: 1834-1844 (2008).
81. Ammendola R, Mesuraca M, Russo T, Cimino F. The DNAbinding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483-489 (1994).
82. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 32: 4100-4108 (2004).
83. Dosunmu R, Wu J, Adwan L, Maloney B, Basha MR, McPherson CA, et al. Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis 18: 211-230 (2009).
84. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19: 739-749 (2005).
85. Saquib Q, Al-Khedhairy AA, Singh BR, Arif JM, Musarrat J. Genotoxic fungicide methyl thiophanate as an oxidative stressor inducing 8-oxo-7,8-dihydro-2'-deoxyguanosine adducts in DNA and mutagenesis. J Environ Sci Health B 45: 40-45 (2010).
86. Bagchi D, Bagchi M, Hassoun EA, Stohs SJ. In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology 104: 129-140 (1995).
87. Weill FS, Cela EM, Ferrari A, Paz ML, Leoni J, Gonzalez Maglio DH. Skin exposure to chronic but not acute UV radiation affects peripheral T-cell function. J Toxicol Environ Health A 74: 838-847 (2011).
88. Risom L, Moller P, Loft S. Oxidative stress-induced DNA damage by particulate air pollution. Mutat Res 592: 119-137 (2005).
89. Djuric Z, Lewis SM, Lu MH, Mayhugh M, Tang N, Hart RW. Effect of varying dietary fat levels on rat growth and oxidative DNA damage. Nutr Cancer 39: 214-219 (2001).
90. Croteau DL, de Souza-Pinto NC, Harboe C, Keijzers G, Zhang Y, Becker K, et al. DNA repair and the accumulation of oxidatively damaged DNA are affected by fruit intake in mice. J Gerontol A Biol Sci Med Sci 65: 1300-1311 (2010).
91. Thompson HJ, Heimendinger J, Diker A, O'Neill C, Haegele A, Meinecke B, et al. Dietary botanical diversity affects the reduction of oxidative biomarkers in women due to high vegetable and fruit intake. J Nutr 136: 2207-2212 (2006).
92. Cui L, Hofer T, Rani A, Leeuwenburgh C, Foster TC. Comparison of lifelong and late life exercise on oxidative stress in the cerebellum. Neurobiol Aging 30: 903-909 (2009).
93. Bloomer RJ, Fisher-Wellman KH. Blood oxidative stress biomarkers: influence of sex, exercise training status, and dietary intake. Gend Med 5: 218-228 (2008).
94. Pinlaor S, Ma N, Hiraku Y, Yongvanit P, Semba R, Oikawa S, et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2'-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis 25:1535-1542 (2004).
95. Narushima S, Spitz DR, Oberley LW, Toyokuni S, Miyata T, Gunnett CA, et al. Evidence for oxidative stress in NSAID-induced colitis in IL10-/-mice. Free Radic Biol Med 34: 1153-1166 (2003).
96. Shen Z, Wu W, Hazen SL. Activated leukocytes oxidatively damage DNA, RNA, and the nucleotide pool through halidedependent formation of hydroxyl radical. Biochemistry 39: 5474-5482 (2000).
97. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 46: 1241-1249 (2009).
98. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 33: 1372-1379 (2002).
99. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36: 1307-1313 (2002).
100. Kikuchi Y, Yasuhara T, Agari T, Kondo A, Kuramoto S, Kameda M, et al. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J Cell Physiol 226: 1390-1398 (2010).
101. Paschos K, Allday MJ. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol 18: 439-447 (2010).
102. Feng Q, Zhang Y. The NuRD complex: linking histone modification to nucleosome remodeling. Curr Top Microbiol Immunol 274: 269-290 (2003).
103. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling. Anticancer Res 31: 2723-2732 (2011).
104. Chodavarapu RK, Feng S, Bernatavichute YV, Chen PY, Stroud H, Yu Y, et al. Relationship between nucleosome positioning and DNA methylation. Nature 466: 388-392 (2010).
105. Kim HS, Kim EM, Kim NJ, Chang KA, Choi Y, Ahn KW, et al. Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-terminal fragments of amyloid precursor protein. J Neurosci Res 75:117-124 (2004).
106. Francis YI, Fa M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18: 131-139 (2009).
107. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35: 870-880 (2010).
108. Manzo F, Tambaro FP, Mai A, Altucci L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 19: 761-774 (2009).
109. Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, Kewitt K, et al. Does oxidative damage to DNA increase with age? Proc Natl Acad Sci USA 98: 10469-10474 (2001).
110. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2: e895 (2007).
111. Osorio FG, Varela I, Lara E, Puente XS, Espada J, Santoro R, et al. Nuclear envelope alterations generate an aging-like epigenetic pattern in mice deficient in Zmpste24 metalloprotease. Aging Cell 9: 947-957 (2010).
112. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet 25: 294-297 (2000).
113. de Magalhaes JP, Curado J, Church GM. Meta-analysis of agerelated gene expression profiles identifies common signatures of aging. Bioinformatics 25: 875-881 (2009).
114. Levenson VV. DNA methylation as a universal biomarker. Expert Rev Mol Diagn 10: 481-488 (2010).
115. Lahiri DK, Maloney B. Genes are not our destiny: the somatic epitype bridges between the genotype and the phenotype. Nat Rev Neurosci 7: doi:10.1038/nrn2022-c1: (2006).
116. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28: 3-9 (2008).
117. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics 82: 696-711 (2008).
118. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 68: 880-891 (2009).
119. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 55: 809-815 (1998).
120. Bihaqi SW, Schumacher A, Maloney B, Zhang Y, Lahiri DK, Zawia NH. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res. [Epub ahead of print] (2012).
121. Perry C, Mackay-Sim A, Feron F, McGrath J. Olfactory neural cells: an untapped diagnostic and therapeutic resource. The 2000 Ogura Lecture. Laryngoscope 112: 603-607 (2002).
122. Lahiri DK. An integrated approach to genome studies. Science 331: 147 (2011).
123. Chan A, Shea TB. Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. J Alzheimers Dis 10: 353-358 (2006).
124. Rogers EJ, Milhalik S, Orthiz D, Shea TB. Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. J Nutr Health Aging 8: 92-97 (2004).
125. Dugger BN, Tu M, Murray ME, Dickson DW. Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Neuroscience letters 491: 122-126 (2011).
126. Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 63: 1771-1776 (2006).
127. Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, et al. Melatonin protects SHSY5Y neuroblastoma cells from cobaltinduced oxidative stress, neurotoxicity and increased beta-amyloid secretion. Journal of Pineal Research 31: 320-325 (2001).
128. Mayurasakorn K, Williams JJ, Ten VS, Deckelbaum RJ. Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hypoxia and ischemia. Curr Opin Clin Nutr Metab Care 14: 158-167 (2011).
129. Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44: 192-201 (2011).
130. Spencer JP, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Mol Aspects Med 33(1): 83-97 (2011).
131. de Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM. Neuroprotective effects of a specific multinutrient intervention against abeta42-induced toxicity in rats. J Alzheimers Dis 27: 327-339 (2011).
132. Lafenetre P, Leske O, Wahle P, Heumann R. The beneficial effects of physical activity on impaired adult neurogenesis and cognitive performance. Front Neurosci 5: 51 (2011).
133. McKay JA, Mathers JC. Diet induced epigenetic changes and their implications for health. Acta Physiol (Oxf) 202: 103-118 (2011).
134. Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med 128: 32-38 (2004).
135. Forti P, Pisacane N, Rietti E, Lucicesare A, Olivelli V, Mariani E, et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 58: 487-492 (2010).
136. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11: 1193-1206 (2010).
137. Sookoian S, Pirola CJ. Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep 13: 149-157 (2011).
138. Montella M, Polesel J, Talamini R, Crispo A, Giudice A, Izzo F, et al. Metabolic Syndrome Is Also a Risk Factor for Primary Liver Cancer in Patients Younger than 65 Years of Age? Hepatology 54(6): 2277-8. doi: 10.1002/hep.24643. (2011).
139. Jousse C, Parry L, Lambert-Langlais S, Maurin AC, Averous J, Bruhat A, et al. Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome. FASEB J 25: 3271-3278 (2011).
140. Sugii S, Evans RM. Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett 585: 2121-2128 (2011).
141. Sebert S, Sharkey D, Budge H, Symonds ME. The early programming of metabolic health: is epigenetic setting the missing link? Am J Clin Nutr 94(6 Suppl):1953S-1958S. (2011).
142. Flory JD, Bierer LM, Yehuda R. Maternal exposure to the holocaust and health complaints in offspring. Dis Markers 30: 133-139 (2011).
143. Bruce KD, Cagampang FR. Epigenetic priming of the metabolic syndrome. Toxicol Mech Methods 21: 353-361 (2011).
144. Lopez-Jaramillo P, Lahera V, Lopez-Lopez J. Epidemic of cardiometabolic diseases: a Latin American point of view. Ther Adv Cardiovasc Dis 5: 119-131 (2011).
145. Pentinat T, Ramon-Krauel M, Cebria J, Diaz R, Jimenez-Chillaron JC. Transgenerational inheritance of glucose intolerance in a mouse model of neonatal overnutrition. Endocrinology 151: 5617-5623 (2010).
146. De Luca C, Scordo G, Cesareo E, Raskovic D, Genovesi G, Korkina L. Idiopathic environmental intolerances (IEI): from molecular epidemiology to molecular medicine. Indian J Exp Biol 48: 625-635 (2010).
147. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neuroscience letters 482: 235-239 (2010).
148. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev 44: 273-282 (2004).
149. King L. Candy Dynamics expands recall to all Toxic Waste® brand Nuclear Sludge® products all flavors and all sizes, http://www.fda.gov/Safety/Recalls/ucm241359.htm. Recalls, Market Withdrawals, and Safety Alerts (2011), Accessed: 1/28/11.
150. Dolinoy DC, Huang D and Jirtle RL. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S A 104: 13056-13061 (2007).
151. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66: 223-227 (2006).
152. Lahiri DK, Maloney B., Basha M.R, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (Latent Early-Life Associated Regulation) may explain the triggering of AD. Curr Alzheimer Res 4:219-228 (2007).
153. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontology 9:375-379 (2008).
154. Zawia NH, Lahiri DK. Epigenetics: A paradigm shift in understanding Alzheimer's Disease. Curr Alzheimer Res [Epub ahead of print] (2012).